Patents by Inventor Samuel Reichgott
Samuel Reichgott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11426105Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: GrantFiled: June 18, 2019Date of Patent: August 30, 2022Assignee: Masimo CorporationInventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Publication number: 20190357823Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: June 18, 2019Publication date: November 28, 2019Inventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 10368787Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: GrantFiled: May 13, 2015Date of Patent: August 6, 2019Assignee: MASIMO CORPORATIONInventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Publication number: 20160058347Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: May 13, 2015Publication date: March 3, 2016Inventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 9060721Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: GrantFiled: October 25, 2013Date of Patent: June 23, 2015Assignee: GLT ACQUISITION CORP.Inventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Publication number: 20140051952Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicant: GLT ACQUISITION CORP.Inventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 8571617Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: GrantFiled: March 4, 2009Date of Patent: October 29, 2013Assignee: GLT Acquisition Corp.Inventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 7640571Abstract: A method and device prevent a set-top terminal from accepting a download of new programming or data over a cable network when the download would be redundant of information already possessed by the set-top terminal or would cause an inconvenience to subscribers. When the set-top terminal is signaled that a new download is being offered, the set-top terminal checks to see if the download in fact contains a newer version of data or programming than is currently resident in the set-top terminal. The set-top terminal also checks whether criteria for accepting a download are met. The criteria are conditions that tend to indicate that an interruption of service to accept a download would not inconvenience the subscriber at that time. When the criteria are met, the download is accepted. Otherwise, the download is not accepted or is not accepted until the criteria are satisfied.Type: GrantFiled: July 15, 1999Date of Patent: December 29, 2009Assignee: General Instrument CorporationInventors: Samuel Reichgott, Abhijit Chatterjee, Charles Schell
-
Publication number: 20090275812Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: March 4, 2009Publication date: November 5, 2009Applicant: GlucoLight CorporationInventors: Samuel Reichgott, Walter J. Shakespeare, George Kechter, Phillip William Wallace, Matthew J. Schurman